Company: BOLT
Filing Date: 2025-06-04
Form Type: 8-K
Source: 0000950170-25-081607
Chunk: 0

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-06-04
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events.

On May 27, 2025, the Board of Directors of Bolt Biotherapeutics, Inc., a Delaware corporation (the “ Company”), approved the filing with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Certificate of Incorporation (the “ Amendment”), to effect a one-for-twenty (1:20) reverse stock split of its outstanding common stock, effective as of 5:00 p. m. eastern time on June 6, 2025 (the “ Reverse Stock Split”). A series of alternate amendments to effect the Reverse Stock Split was approved by the Company’s stockholders at the Annual Meeting of Stockholders held on May 27, 2025, and the specific one-for-twenty (1:20) ratio was subsequently approved by the Company’s Board of Directors on May 27, 2025.

The Amendment provides that at the effective time of the Reverse Stock Split, every 20 shares of the Company’s issued and outstanding common stock will be automatically converted into one issued and outstanding share of common stock, without any change in par value per share. The Reverse Stock Split will affect all shares of the Company’s common stock outstanding immediately prior to the effective time of the Reverse Stock Split, as well as the number of shares of common stock available for issuance under the Company’s equity incentive plans and employee stock purchase plan. In addition, the Reverse Stock Split will effect a reduction in the number of shares of common stock issuable upon the exercise of stock options, restricted stock units and warrants outstanding immediately prior to the effectiveness of the Reverse Stock Split with a corresponding increase in the exercise price per share applicable to such stock options and warrants. No fractional shares will be issued because of the Reverse Stock Split. Stockholders who would otherwise be entitled to receive a fractional share will receive a cash payment in lieu thereof.

The Company’s common stock is scheduled to begin trading on the Nasdaq Capital Market on a split-adjusted basis when the market opens on June 9, 2025 under the existing ticker symbol “ BOLT”. The new CUSIP number for the common stock following the Reverse Stock Split is 097702203. The par value per share of the common stock will remain unchanged at $0.00001.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                                        Bolt Bio